Twist Bioscience Corp(TWST)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,367 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
TWST Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Twist Bioscience Corp (TWST), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TWST at 33.9/100 on a 32-signal composite quality model, placing it at rank #2,367 of 2,961 stocks — the bottom half of the AI-ranked universe. TWST scores in the top quartile across revenue growth (81.6). Areas of concern include balance sheet strength (10.8) and free cash flow (12.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Twist Bioscience Corp reports quarterly revenue of $118.4M, net income of $-35.1M, an operating margin of -30.6%. Top institutional holders of TWST by reported 13-F value include BlackRock, Artisan Partners Limited Partnership, FMR, based on the most recent SEC filings. TWST trades on the Nasdaq exchange and files with the SEC under CIK 1581280. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TWST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Twist Bioscience Corp directly from SEC EDGAR. Twist Bioscience Corp's 13F Pro composite quality score has ranged between 27 and 36 since 2023, currently 33.9 — an improving long-term trajectory across 55 quarterly and live scoring snapshots.
Revenue
Q2 2026
$118.4M
Net Income
Q2 2026
$-35.1M
Free Cash Flow
Q2 2026
$-8.6M
Operating Margin
Q2 2026
-30.6%
ROIC
Q2 2026
-32.6%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+20.3% YoYNet Income
+62.8% YoYOperating Income
+38.3% YoYEPS (Diluted)
+63.9% YoYTotal Assets
+4.5% YoYTotal Debt
Op. Cash Flow
+25.7% YoYFree Cash Flow
-9.3% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $376.6M +20.3% | $313.0M +27.7% | $245.1M +20.4% | $203.6M +53.8% | $132.3M +46.9% | $90.1M |
| Net Income | $-77.7M +62.8% | $-208.7M -2.0% | $-204.6M +6.1% | $-217.9M -43.2% | $-152.1M -8.7% | $-139.9M |
| Operating Income | $-136.3M +38.3% | $-220.8M -1.7% | $-217.2M +7.5% | $-234.8M -53.7% | $-152.7M -9.0% | $-140.1M |
| EPS (Diluted) | $-1.30 +63.9% | $-3.60 +0.0% | $-3.60 +10.9% | $-4.04 -28.3% | $-3.15 +11.8% | $-3.57 |
| Total Assets | $641.9M +4.5% | $614.3M -20.9% | $776.4M -19.2% | $961.4M +36.9% | $702.1M +76.0% | $398.9M |
| Total Debt | — | — | — | $0.00 -100.0% | $1.6M -79.3% | $7.5M |
| Operating Cash Flow | $-47.6M +25.7% | $-64.1M +55.0% | $-142.5M -14.5% | $-124.4M -10.8% | $-112.2M +21.1% | $-142.3M |
| Free Cash Flow | $-75.6M -9.3% | $-69.2M +59.4% | $-170.3M +24.7% | $-226.2M -62.4% | $-139.3M +8.4% | $-152.1M |
Get alerted when TWST's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Twist Bioscience Corp including:
Top Institutional Holders of TWST
BlackRock, Inc.
$600.2M5,833,891 shArtisan Partners Limited Partnership
$494.0M4,802,017 shFMR LLC
$483.8M4,703,044 shARK Investment Management LLC
$468.1M4,549,803 shPRICE T ROWE ASSOCIATES INC /MD/
$373.9M3,634,652 shSTATE STREET CORP
$332.6M3,232,532 shVANGUARD PORTFOLIO MANAGEMENT LLC
$290.6M2,824,989 shVANGUARD CAPITAL MANAGEMENT LLC
$277.7M2,699,280 shEdgePoint Investment Group Inc.
$259.4M2,521,635 shWILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
$223.7M2,174,594 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $600.2M | 5,833,891 |
| Artisan Partners Limited Partnership | $494.0M | 4,802,017 |
| FMR LLC | $483.8M | 4,703,044 |
| ARK Investment Management LLC | $468.1M | 4,549,803 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $373.9M | 3,634,652 |
| STATE STREET CORP | $332.6M | 3,232,532 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $290.6M | 2,824,989 |
| VANGUARD CAPITAL MANAGEMENT LLC | $277.7M | 2,699,280 |
| EdgePoint Investment Group Inc. | $259.4M | 2,521,635 |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $223.7M | 2,174,594 |
Companies Similar to TWST
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Guardant Health, Inc.
NeuroPace Inc
Mirum Pharmaceuticals, Inc.
RHYTHM PHARMACEUTICALS, INC.
Adaptive Biotechnologies Corp
GeneDx Holdings Corp.
BridgeBio Pharma, Inc.
MADRIGAL PHARMACEUTICALS, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put TWST on your watchlist
Track score changes the day Twist Bioscience Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TWST a good stock to buy?
13F Pro's AI-powered analysis of Twist Bioscience Corp (TWST) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TWST are available on the TWST stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TWST is classified as a mid company.
Which hedge funds own TWST?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TWST. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Twist Bioscience Corp's investment landscape.